Intraperitoneal Injection is Not Always a Suitable Alternative to Intravenous Injection for Radiotherapy
UMass Chan AffiliationsDepartment of Radiology
Document TypeJournal Article
Amino Acids, Peptides, and Proteins
Animal Experimentation and Research
MetadataShow full item record
AbstractAbstract Intraperitoneal (IP) injection is frequently reported to be as effective as intravenous (IV) injection. Because it allows administering a larger volume with more radioactivity, we have investigated this route and the possibility of using it to circumvent the volume constraint we earlier experienced with pretargeting radiotherapy. Using 99mTc as the label, the pharmacokinetics (PK) of the cMORF effector (a DNA analogue) was evaluated after IP or IV injection in normal mice by necropsy and SPECT/CT imaging. In another experiment, nude mice bearing tumors were used and they received MORF-CC49 pretargeting antibody IV 2 days earlier than labeled cMORF IV or IP. Tumor accumulations of cMORF were measured at 6 hours after its injections. The absorbed radiation doses for 188Re or 90Y pretargeting were estimated using the 99mTc data and a self-absorbed model. Although the absorbed radiation doses to other organs were comparable, the dose to intestines after IP injection was 30-fold higher than IV injection due to the slow entry into the circulation. It had reached such a level as high as the dose to the kidneys that cleared the radioactivity and usually were at the highest level. Nevertheless, the slow entry did not reduce the tumor accumulation. In conclusion, using IP in place of IV led to an unacceptably high absorbed radiation dose to the intestines although the tumor accumulation was not compromised. This effect may be applicable to other radiotherapeutic agents as well.
Shuping Dou, Miles Smith, Yuzhen Wang, Mary Rusckowski, and Guozheng Liu. Cancer Biotherapy and Radiopharmaceuticals. May 2013, 28(4): 335-342. doi:10.1089/cbr.2012.1351. Link to article on publisher's site
Permanent Link to this Itemhttp://hdl.handle.net/20.500.14038/29218
RightsThis is a copy of an article published in the journal Cancer Biotherapy and Radiopharmaceuticals, copyright 2013 Mary Ann Liebert, Inc. Article is available online at: http://online.liebertpub.com. Publisher PDF posted as allowed by the publisher's author rights policy at http://www.liebertpub.com/nv/resources-tools/self-archiving-policy/51/.
Showing items related by title, author, creator and subject.
DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculationsFynan, Ellen F.; Webster, Robert G.; Fuller, D H; Haynes, Joel R.; Santoro, Joseph C.; Robinson, Harriet L. (1993-12-15)Plasmid DNAs expressing influenza virus hemagglutinin glycoproteins have been tested for their ability to raise protective immunity against lethal influenza challenges of the same subtype. In trials using two inoculations of from 50 to 300 micrograms of purified DNA in saline, 67-95% of test mice and 25-63% of test chickens have been protected against a lethal influenza challenge. Parenteral routes of inoculation that achieved good protection included intramuscular and intravenous injections. Successful mucosal routes of vaccination included DNA drops administered to the nares or trachea. By far the most efficient DNA immunizations were achieved by using a gene gun to deliver DNA-coated gold beads to the epidermis. In mice, 95% protection was achieved by two immunizations with beads loaded with as little as 0.4 micrograms of DNA. The breadth of routes supporting successful DNA immunizations, coupled with the very small amounts of DNA required for gene-gun immunizations, highlight the potential of this remarkably simple technique for the development of subunit vaccines.
The Influence of Spatial Proximity to Syringe Services Programs and Secondary Syringe Exchange on the Risk of Hepatitis C Virus Infection Among Rural People Who Inject DrugsRomo, Eric (2022-04-01)Background: Rural people who inject drugs (PWID) have been disproportionately affected by the ongoing hepatitis C virus (HCV) epidemic. Methods: Using data from a cross-sectional study of PWID from rural New Hampshire, Vermont, and Massachusetts, we evaluated the potential for syringe services programs (SSPs) to lower the risk of HCV infection among rural PWID via their influence on the physical and social environment. The specific aims were to evaluate: 1) the association of spatial proximity to the nearest SSP with HCV seroprevalence and injection risk behaviors; 2) the association of indirect SSP use (secondary syringe exchange) with HCV seroprevalence and injection risk behaviors; and to 3) explore PWIDs’ perceptions and experiences with obtaining injection supplies, injection risk behaviors, and HCV. Results: Living farther from an SSP was associated with a higher prevalence of HCV seropositivity and injection risk behaviors. Indirect SSP use was weakly and imprecisely associated with lower prevalence of injection risk behaviors, while direct SSP and pharmacy use were both associated with a higher prevalence of HCV seropositivity and injection risk behaviors. Participants described sharing syringes in response to limited access to syringe sources. Syringe sharing behavior was influenced by perceptions of HCV risk, HCV status, and emotions of trust and intimacy. Conclusion: Spatial proximity to an SSP and direct use of an SSP may lower the risk of HCV infection among rural PWID. HCV prevention efforts in rural New England need to address syringe access and cultivate the perception that HCV is a serious but preventable risk.
A comparison of brain and behavioral effects of varenicline and nicotine in ratsKing, Jean A.; Huang, Wei; Chen, Wei; Heffernan, Meghan E.; Shields, Jessica; Rane, Pallavi; Bircher, Rhiannon; DiFranza, Joseph R. (2011-09-30)We evaluated the effects of the smoking cessation aid varenicline and nicotine on brain activation, locomotor sensitization and cognitive functioning in rats. Blood oxygenation level dependent (BOLD) activation on fMRI was measured in awake adult male Sprague-Dawley rats in response to their first dose of varenicline 0.04 mg/kg administered intravenously and compared to saline controls. Other groups of rats were pretreated with daily injections of either varenicline 0.04 mg/kg or saline administered subcutaneously over 5 days, and then imaged on the sixth day while receiving an intravenous dose. The initial dose of varenicline produced patterns of brain activation similar to those previously seen with nicotine, increasing BOLD activation in the auditory, cingulate, insular, prefrontal, retrosplenial, temporal and visual cortices, as well as the hippocampus, nucleus accumbens, septum, and ventral tegmental area. However, the sixth dose produced significantly less BOLD activation than the initial dose in the hippocampus, insular cortex, prefrontal cortex, and temporal cortex, suggesting tolerance. Repeated doses of varenicline have thus the opposite effect of repeated nicotine dosing at 24h intervals, previously shown to produce sensitization of brain activation under the same experimental conditions. We also assessed the effects of varenicline on locomotor sensitization and performance in the Morris water maze. Compared to saline controls, varenicline treated rats showed no evidence of locomotor activation or sensitization, and showed improved performance times on the water maze only on the first day. This study points to different effects of varenicline and nicotine on neuronal and behavioral indices.